Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.58 |
| ▸ | CCR2 | P41597 | 9/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377255 | 0.83 | ALDH1A1 (0.58) | POLBL3MBTL1MEP1BCCR2TSHR | |
| SCHEMBL6832021 | 0.83 | POLB (0.62) | POLBL3MBTL1MEP1BCCR2TSHR | |
| SCHEMBL172392 | 0.81 | CCR2 (0.58) | POLBL3MBTL1MEP1BCCR2TSHR | |
| SCHEMBL10804574 | 0.81 | MAPT (0.69) | MEP1BCCR2TSHRTP53MAPT | |
| SCHEMBL27790847 | 0.81 | MEP1B (0.71) | POLBL3MBTL1MEP1BCCR2TSHR | |
| SCHEMBL6209362 | 0.80 | MEP1B (0.54) | POLBL3MBTL1MEP1BCCR2TSHR | |
| SCHEMBL2371885 | 0.80 | KIF11 (0.55) | POLBL3MBTL1MEP1BKIF11VCAM1 | |
| SCHEMBL11697492 | 0.80 | FFAR4 (0.57) | L3MBTL1KIF11ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18714236 | 0.79 | POLB (0.73) | POLBL3MBTL1MEP1BCCR2TSHR | |
| SCHEMBL127681 | 0.79 | MEP1B (0.52) | POLBL3MBTL1MEP1BCCR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
| WO-2007070947-A1 | ANTIBACTERIAL AGENTS | ALCHEMIA LTD (AU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023669-A1 | Antibacterial Agents | MRPL21, FUT6, FUT5 | POLB 3470/4885L3MBTL1 3195/4885MEP1B 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.